DOJ Asks To Join Wyeth Rapamune Qui Tam Suit
The U.S. Department of Justice sought permission Tuesday to join a whistleblower suit accusing Wyeth Pharmaceuticals Inc. of illegally marketing kidney transplant drug Rapamune for use in other, unapproved organ transplant...To view the full article, register now.
Already a subscriber? Click here to view full article